La Jolla Pharmaceutical Co. (NASDAQ:LJPC) shot up 5.3% during mid-day trading on Thursday . The company traded as high as $18.44 and last traded at $18.38, with a volume of 62,633 shares traded. The stock had previously closed at $17.45.

A number of brokerages have issued reports on LJPC. Zacks Investment Research raised La Jolla Pharmaceutical from a “hold” rating to a “buy” rating and set a $21.00 target price for the company in a research report on Thursday. SunTrust Banks Inc. began coverage on La Jolla Pharmaceutical in a research report on Wednesday, June 22nd. They set a “buy” rating and a $30.00 target price for the company. Jefferies Group reaffirmed a “buy” rating on shares of La Jolla Pharmaceutical in a research report on Wednesday, June 8th. Finally, Lake Street Capital began coverage on La Jolla Pharmaceutical in a research report on Tuesday, May 24th. They set a “buy” rating and a $25.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus target price of $38.83.

The firm’s 50 day moving average is $16.85 and its 200-day moving average is $17.61. The firm’s market capitalization is $332.41 million.

La Jolla Pharmaceutical (NASDAQ:LJPC) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.99) by $0.09. Equities analysts anticipate that La Jolla Pharmaceutical Co. will post ($3.80) EPS for the current fiscal year.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.